Author： Menten Johan Carpentier Isabelle Deschutter Harlinde Nuyts Sandra Van Beek Karen
Publisher： Informa Healthcare
ISSN： 0735-7907
Source： Cancer Investigation, Vol.31, Iss.6, 2013-07, pp. : 412-420
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ≥2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day.
Related content
Radiotherapy for head and neck cancer in elderly patients
By Schofield C.P. Sykes A.J. Slevin N.J. Rashid N.Z.Z.
Radiotherapy and Oncology, Vol. 69, Iss. 1, 2003-10 ,pp. :
Access to resources
Recommend
By Pajares B. Perez-Villa L. Trigo J. Toledo M. Álvarez M. Jimenez B. Medina J. Luque V. Jerez J. Alba E.
Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. :
By Nicolatou-Galitis O. Sotiropoulou-Lontou A. Velegraki A. Pissakas G. Kolitsi G. Kyprianou K. Kouloulias V. Papanikolaou I. Yiotakis I. Dardoufas K.
Oral Oncology, Vol. 39, Iss. 4, 2003-06 ,pp. :